Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors
It is difficult to predict the clinical outcome for patients with ovarian cancer. However, the use of biomarkers as additional prognostic factors may improve the outcome for these patients. In order to find novel candidate biomarkers, differences in gene expressions were analysed in 54 stage III ser...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2006-11, Vol.42 (16), p.2846-2854 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2854 |
|---|---|
| container_issue | 16 |
| container_start_page | 2846 |
| container_title | European journal of cancer (1990) |
| container_volume | 42 |
| creator | Partheen, Karolina Levan, Kristina Österberg, Lovisa Horvath, György |
| description | It is difficult to predict the clinical outcome for patients with ovarian cancer. However, the use of biomarkers as additional prognostic factors may improve the outcome for these patients. In order to find novel candidate biomarkers, differences in gene expressions were analysed in 54 stage III serous ovarian adenocarcinomas with oligonucleotide microarrays containing 27,000 unique probes. The microarray data was verified with quantitative real-time polymerase chain reaction for the genes
TACC1,
MUC5B and
PRAME. Using hierarchical cluster analysis we detected a sub-group that included 60% of the survivors. The gene expressions in tumours from patients in this sub-group of survivors were compared with the remaining tumours, and 204 genes were found to be differently expressed. We conclude that the sub-group of survivors might represent patients with favourable tumour biology and sensitivity to treatment. A selection of the 204 genes might be used as a predictive model to distinguish patients within and outside of this group. Alternative chemotherapy strategies could then be offered as first-line treatment, which may lead to improvements in the clinical outcome for these patients. |
| doi_str_mv | 10.1016/j.ejca.2006.06.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68983623</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804906006551</els_id><sourcerecordid>68983623</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-85864e102813c9fa342a1c920fb556fda3593ee3d0a7d51b776c7ab3b01aec583</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVJaTZp_0APxZf05q0-bFmCXsqSJguBXtqzGMvjrRavtdXYS_PvK3cXcgsMCIbnfRk9jH0UfC240F_2a9x7WEvO9XoZqd-wlTCNLbmp5RVbcVvb0vDKXrMboj3nvDEVf8euhbZWSy1WDO__HhMShTgWMMLwTIGK2Bc0wQ6L7XZbEKY4590JUoAMdThGD8mHMR6g6AJNYdzNgX4jFVDQ3Ja7HDj-L5nTKZxiovfsbQ8D4YfLe8t-fb__uXksn348bDffnkqvTDWVpja6QsGlEcrbHlQlQXgred_Wte47ULVViKrj0HS1aJtG-wZa1XIB6Gujbtnnc-8xxT8z0uQOgTwOA4yYP-G0sUZpqTIoz6BPkShh744pHCA9O8HdItft3SLXLXLdMlLn0KdL-9wesHuJXGxm4O4CAHkY-gSjD_TCmVxizcJ9PXOYXZwCJkc-4OixCwn95LoYXrvjH3oImXw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68983623</pqid></control><display><type>article</type><title>Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Partheen, Karolina ; Levan, Kristina ; Österberg, Lovisa ; Horvath, György</creator><creatorcontrib>Partheen, Karolina ; Levan, Kristina ; Österberg, Lovisa ; Horvath, György</creatorcontrib><description>It is difficult to predict the clinical outcome for patients with ovarian cancer. However, the use of biomarkers as additional prognostic factors may improve the outcome for these patients. In order to find novel candidate biomarkers, differences in gene expressions were analysed in 54 stage III serous ovarian adenocarcinomas with oligonucleotide microarrays containing 27,000 unique probes. The microarray data was verified with quantitative real-time polymerase chain reaction for the genes
TACC1,
MUC5B and
PRAME. Using hierarchical cluster analysis we detected a sub-group that included 60% of the survivors. The gene expressions in tumours from patients in this sub-group of survivors were compared with the remaining tumours, and 204 genes were found to be differently expressed. We conclude that the sub-group of survivors might represent patients with favourable tumour biology and sensitivity to treatment. A selection of the 204 genes might be used as a predictive model to distinguish patients within and outside of this group. Alternative chemotherapy strategies could then be offered as first-line treatment, which may lead to improvements in the clinical outcome for these patients.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2006.06.026</identifier><identifier>PMID: 16996261</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cluster Analysis ; Cystadenocarcinoma, Serous - genetics ; Cystadenocarcinoma, Serous - metabolism ; Cystadenocarcinoma, Serous - mortality ; Expression array ; Female ; Gene expression ; Genetic Linkage ; Humans ; Medical sciences ; Microarray ; Middle Aged ; MUC5B ; Oligonucleotide Array Sequence Analysis ; Ovarian cancer ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - mortality ; Pharmacology. Drug treatments ; Polymerase Chain Reaction - methods ; PRAME ; Prognostic factors ; Survival ; Survivors - statistics & numerical data ; TACC1 ; Tumors ; Tumour marker</subject><ispartof>European journal of cancer (1990), 2006-11, Vol.42 (16), p.2846-2854</ispartof><rights>2006 Elsevier Ltd</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-85864e102813c9fa342a1c920fb556fda3593ee3d0a7d51b776c7ab3b01aec583</citedby><cites>FETCH-LOGICAL-c384t-85864e102813c9fa342a1c920fb556fda3593ee3d0a7d51b776c7ab3b01aec583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejca.2006.06.026$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18263981$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16996261$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Partheen, Karolina</creatorcontrib><creatorcontrib>Levan, Kristina</creatorcontrib><creatorcontrib>Österberg, Lovisa</creatorcontrib><creatorcontrib>Horvath, György</creatorcontrib><title>Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>It is difficult to predict the clinical outcome for patients with ovarian cancer. However, the use of biomarkers as additional prognostic factors may improve the outcome for these patients. In order to find novel candidate biomarkers, differences in gene expressions were analysed in 54 stage III serous ovarian adenocarcinomas with oligonucleotide microarrays containing 27,000 unique probes. The microarray data was verified with quantitative real-time polymerase chain reaction for the genes
TACC1,
MUC5B and
PRAME. Using hierarchical cluster analysis we detected a sub-group that included 60% of the survivors. The gene expressions in tumours from patients in this sub-group of survivors were compared with the remaining tumours, and 204 genes were found to be differently expressed. We conclude that the sub-group of survivors might represent patients with favourable tumour biology and sensitivity to treatment. A selection of the 204 genes might be used as a predictive model to distinguish patients within and outside of this group. Alternative chemotherapy strategies could then be offered as first-line treatment, which may lead to improvements in the clinical outcome for these patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cluster Analysis</subject><subject>Cystadenocarcinoma, Serous - genetics</subject><subject>Cystadenocarcinoma, Serous - metabolism</subject><subject>Cystadenocarcinoma, Serous - mortality</subject><subject>Expression array</subject><subject>Female</subject><subject>Gene expression</subject><subject>Genetic Linkage</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Microarray</subject><subject>Middle Aged</subject><subject>MUC5B</subject><subject>Oligonucleotide Array Sequence Analysis</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymerase Chain Reaction - methods</subject><subject>PRAME</subject><subject>Prognostic factors</subject><subject>Survival</subject><subject>Survivors - statistics & numerical data</subject><subject>TACC1</subject><subject>Tumors</subject><subject>Tumour marker</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVJaTZp_0APxZf05q0-bFmCXsqSJguBXtqzGMvjrRavtdXYS_PvK3cXcgsMCIbnfRk9jH0UfC240F_2a9x7WEvO9XoZqd-wlTCNLbmp5RVbcVvb0vDKXrMboj3nvDEVf8euhbZWSy1WDO__HhMShTgWMMLwTIGK2Bc0wQ6L7XZbEKY4590JUoAMdThGD8mHMR6g6AJNYdzNgX4jFVDQ3Ja7HDj-L5nTKZxiovfsbQ8D4YfLe8t-fb__uXksn348bDffnkqvTDWVpja6QsGlEcrbHlQlQXgred_Wte47ULVViKrj0HS1aJtG-wZa1XIB6Gujbtnnc-8xxT8z0uQOgTwOA4yYP-G0sUZpqTIoz6BPkShh744pHCA9O8HdItft3SLXLXLdMlLn0KdL-9wesHuJXGxm4O4CAHkY-gSjD_TCmVxizcJ9PXOYXZwCJkc-4OixCwn95LoYXrvjH3oImXw</recordid><startdate>20061101</startdate><enddate>20061101</enddate><creator>Partheen, Karolina</creator><creator>Levan, Kristina</creator><creator>Österberg, Lovisa</creator><creator>Horvath, György</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20061101</creationdate><title>Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors</title><author>Partheen, Karolina ; Levan, Kristina ; Österberg, Lovisa ; Horvath, György</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-85864e102813c9fa342a1c920fb556fda3593ee3d0a7d51b776c7ab3b01aec583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cluster Analysis</topic><topic>Cystadenocarcinoma, Serous - genetics</topic><topic>Cystadenocarcinoma, Serous - metabolism</topic><topic>Cystadenocarcinoma, Serous - mortality</topic><topic>Expression array</topic><topic>Female</topic><topic>Gene expression</topic><topic>Genetic Linkage</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Microarray</topic><topic>Middle Aged</topic><topic>MUC5B</topic><topic>Oligonucleotide Array Sequence Analysis</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymerase Chain Reaction - methods</topic><topic>PRAME</topic><topic>Prognostic factors</topic><topic>Survival</topic><topic>Survivors - statistics & numerical data</topic><topic>TACC1</topic><topic>Tumors</topic><topic>Tumour marker</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Partheen, Karolina</creatorcontrib><creatorcontrib>Levan, Kristina</creatorcontrib><creatorcontrib>Österberg, Lovisa</creatorcontrib><creatorcontrib>Horvath, György</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Partheen, Karolina</au><au>Levan, Kristina</au><au>Österberg, Lovisa</au><au>Horvath, György</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2006-11-01</date><risdate>2006</risdate><volume>42</volume><issue>16</issue><spage>2846</spage><epage>2854</epage><pages>2846-2854</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>It is difficult to predict the clinical outcome for patients with ovarian cancer. However, the use of biomarkers as additional prognostic factors may improve the outcome for these patients. In order to find novel candidate biomarkers, differences in gene expressions were analysed in 54 stage III serous ovarian adenocarcinomas with oligonucleotide microarrays containing 27,000 unique probes. The microarray data was verified with quantitative real-time polymerase chain reaction for the genes
TACC1,
MUC5B and
PRAME. Using hierarchical cluster analysis we detected a sub-group that included 60% of the survivors. The gene expressions in tumours from patients in this sub-group of survivors were compared with the remaining tumours, and 204 genes were found to be differently expressed. We conclude that the sub-group of survivors might represent patients with favourable tumour biology and sensitivity to treatment. A selection of the 204 genes might be used as a predictive model to distinguish patients within and outside of this group. Alternative chemotherapy strategies could then be offered as first-line treatment, which may lead to improvements in the clinical outcome for these patients.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>16996261</pmid><doi>10.1016/j.ejca.2006.06.026</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2006-11, Vol.42 (16), p.2846-2854 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68983623 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Cluster Analysis Cystadenocarcinoma, Serous - genetics Cystadenocarcinoma, Serous - metabolism Cystadenocarcinoma, Serous - mortality Expression array Female Gene expression Genetic Linkage Humans Medical sciences Microarray Middle Aged MUC5B Oligonucleotide Array Sequence Analysis Ovarian cancer Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Ovarian Neoplasms - mortality Pharmacology. Drug treatments Polymerase Chain Reaction - methods PRAME Prognostic factors Survival Survivors - statistics & numerical data TACC1 Tumors Tumour marker |
| title | Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T05%3A34%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20analysis%20of%20stage%20III%20serous%20ovarian%20adenocarcinoma%20distinguishes%20a%20sub-group%20of%20survivors&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Partheen,%20Karolina&rft.date=2006-11-01&rft.volume=42&rft.issue=16&rft.spage=2846&rft.epage=2854&rft.pages=2846-2854&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2006.06.026&rft_dat=%3Cproquest_cross%3E68983623%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68983623&rft_id=info:pmid/16996261&rft_els_id=S0959804906006551&rfr_iscdi=true |